Orphan Drug Designation for trigeminal neuralgia treatment

Image: Envato

Swiss biotech Noema Pharma AG has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to basimglurant (formerly known as NOE-101) for the treatment of trigeminal neuralgia (TN).

TN is a rare, chronic neuropathic pain disorder affecting the trigeminal nerve, characterized by sudden, severe episodes of electric shock-like facial pain that can be triggered by routine daily activities such as eating, drinking, speaking, brushing teeth, shaving, or even light touch or exposure to cold air. Affecting an estimated 150,000 people in the US, TN is widely considered one of the most painful neurological disorders and can significantly impair quality of life and daily functioning, contributing to substantial psychological burden. Despite its severity, treatment options remain limited, with carbamazepine as the only FDA-approved therapy and no significant therapeutic innovations in decades, leaving patients with a high unmet medical need.

Basimglurant is an orally administered, highly potent, cell-penetrant mGluR5 negative allosteric modulator (NAM) designed to modulate both central and peripheral pain pathways implicated in neuropathic pain. Basimglurant previously received FDA Fast Track Designation for TN.

“Receiving Orphan Drug Designation for basimglurant marks an important milestone as we advance the program toward phase 3 development,” said Ilise Lombardo, CEO of Noema Pharma.

“Affecting an estimated 150,000 people in the US, TN is one of the most severe and debilitating chronic neuropathic pain disorders, yet patients have seen limited therapeutic innovation in nearly six decades. This designation supports our efforts to advance basimglurant as a potential first-in-class non-opioid therapy for people living with trigeminal neuralgia.”

Basimglurant (formerly known as NOE-101) is an investigational, orally administered, highly selective metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) being developed for severe neuropathic pain disorders, including TN. Through its cell-penetrant mechanism, basimglurant is designed to modulate both intracellular and cell-surface mGluR5 signalling pathways implicated in chronic neuropathic pain. Basimglurant is an investigational non-opioid treatment with no known abuse potential, and has demonstrated robust and durable reductions across multiple pain domains with a favourable tolerability profile in a phase 2 clinical study.